Best in Biotech 5 Dec 2017 Europe’s Brightest Stars: The 9 Best Biotech Companies of 2017 …candidates through the clinic. The antibody-drug conjugates combine monoclonal antibodies with the company’s specialized pyrrolobenzodiazepine (PBD) dimers as toxins. These molecules cross-link between DNA strands to block cell division and… December 5, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 16 Feb 2021 Cancer Research UK Cuts Two Biotech Collaborations Amid Pandemic Squeeze …trial, suggesting its candidate may at least partially boost the effects of the immunotherapy antibody rituximab in patients with drug-resistant non-Hodgkin’s lymphoma. The company reached its highest share price in… February 16, 2021 - 4 minutesmins - By Anita Chakraverty Share WhatsApp Twitter Linkedin Email
In Depth 14 Apr 2023 mRNA vaccines: a promising future …vaccine that applies a similar mechanism whereby host cells are instructed to make copies of spike proteins to induce an immune response for antibody production. The first COVID 19 vaccine… April 14, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 19 Feb 2018 This Belgian Biotech Gives Us an Update on its Bulging Psoriasis Pipeline …meeting. Belgian biopharma, UCB, develops medicines for people suffering from severe diseases of the immune or central nervous systems. The company is developing a number of candidates for moderate-to-severe chronic… February 19, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2017 ‘Trojan Horse’ Shark Antibodies could beat the Blood Brain Barrier Ossianix, partnered with Lundbeck, is developing shark antibodies that can help therapeutics cross the blood brain barrier. Ossianix develops shark-inspired antibody fragments, VNARs, with outstanding properties thanks to their small… January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Emactuzumab designated as an orphan medicinal product for TGCT in Europe SynOx Therapeutics Limited says its novel monoclonal antibody, emactuzumab, in development for the treatment of tenosynovial giant cell tumor (TGCT) and other diseases, has been designated as an orphan medicinal… August 31, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Feb 2018 Morphosys and Galapagos Announce Positive Phase I Results for Atopic Dermatitis Treatment Phase I results show promise for a new treatment for atopic dermatitis that may become a strong competitor to the market leader, Humira. Morphosys and Galapagos are developing an antibody… February 20, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 7 Oct 2019 UK Biotech Launches with €30M Series A to Treat Autoimmune Disease …money to fund the preclinical development of antibody drugs for unspecified autoimmune diseases. The company will also expand its drug discovery efforts to other unspecified disease areas and grow its… October 7, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Aug 2022 Formulations of Arecor Therapeutics’ drug to treat inflammatory diseases granted patents …issued two patents that will protect Arecor Therapeutics’ formulations of high-concentration adalimumab until 2038. The company made the announcement today (August 9). Monoclonal antibody Adalimumab, sold by AbbVie under the… August 9, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Dec 2016 Better than ADCs? AstraZeneca bids for Bicyclic Peptides …(BDCs) outperform ADCs? Bicycle Therapeutics is a company in Cambridge founded by one of the top biotech leaders in the UK’s golden triangle. Its unique technology to develop antibody-like bicyclic… December 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 14 Jul 2022 Boston startup bags $40M Series A to smash preclinical bottlenecks …of the startup is a type of drugs called targeted effectors. This class, including cell engagers and antibody-drug conjugates, involves attaching a therapeutic payload onto a carrier molecule that delivers… July 14, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Mar 2023 Pfizer’s $43B Seagen acquisition doubles early-stage oncology clinical pipeline …next generation of cancer breakthroughs and bring new solutions to patients by combining the power of Seagen’s antibody-drug conjugate (ADC) technology with the scale and strength of Pfizer’s capabilities and… March 14, 2023 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email